Diranersen / BIIB080 Phase 2
Phase 2 study of BIIB080, an investigational tau-lowering antisense medicine.
Overview
Intrathecal ASO programme. Safety and symptom outcomes are still being established. Trial-only access.
Similar pages
not linked directly; found by shared links- TechnologyBlood Alzheimer biomarkers
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyTau-directed therapeutics
Shares Diranersen (BIIB080), Alzheimer’s disease and the tag dementia-atlas.
- TrialENGAGE
Shares Biogen, Alzheimer’s disease and the tag dementia-atlas.
- TrialTRONTIER 2 (trontinemab Phase 3)
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TrialCLARITY AD
Shares Biogen, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentSemaglutide (EVOKE programme)
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TrialEVOKE (semaglutide in early Alzheimer’s)
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentTrontinemab
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.